From Economy:  NCI T cell attack cancer —  National Cancer Institute \ Duncan Comprehensive Cancer Center at Baylor College of Medicine

From Economy: NCI T cell attack cancer

National Cancer Institute \ Duncan Comprehensive Cancer Center at Baylor College of Medicine

An interesting, detailed article from Alex Lash at Xconomy reviewing the progress of the first two CAR-T therapies approved, Kymriah (from Novartis) and Yescarta (from Gilead Sciences). While the article may seem a bit negative, we think it simply reflects the normal difficulties of introducing a brand new, radically different, medical technology in to a complicated world.

A generation ago, cancer treatments made from a patient’s own living immune cells would have been science fiction. Now they’re here. The first two products, approved in 2017 and known in shorthand as CAR-T, have brought some people with otherwise untreatable blood cancers back from the brink of death.

The experimental results that led to approval for each product were remarkable. But outside the cautious, tightly controlled bubble of clinical studies, the products and their owners have had different experiences in the real world.

Read the full article at Xconomy HERE